



Dr Lal PathLabs

November 6, 2020

National Stock Exchange of India
Limited Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E)
Mumbai – 400 051.

Bombay Stock Exchange Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

**Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated)
for the Quarter and Half Year ended September 30, 2020**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2020.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Rajat Kalra
Company Secretary and Legal Head
Encl: As above



Dr. Lal PathLabs Limited records revenue of Rs 431.9 Cr in Q2 FY 2020-21

New Delhi, India, November 6, 2020 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2020

Consolidated Performance Highlights: Q2 FY 2020-21 vs Q2 FY 2019-20

Revenue: Rs 431.9 Cr, a growth of 18.2%

Normalised EBITDA at Rs 134.7 Cr with margin at 31.2%

PBT at Rs 116.6 Cr with margin at 27.0%, and

PAT Rs 87.1 Cr with margin at 20.2%

- Operating Revenue increased by 18.2% in Q2 FY21 to Rs. 431.9 Cr vs Rs 365.6 Cr in Q2 FY20
- Covid contributed 17% to Revenue in Q2 FY21 with 3.08 lacs. RTPCR tests
- Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q2 FY21 is at Rs. 134.7.0 Cr Vs Rs 113.5 Cr in the same quarter last year
- PBT is at Rs 116.6 Cr in Q2 FY21 vs Rs 102.3 Cr. in Q2 last year
- Profit after Tax in Q2 FY21 at Rs. 87.1 Cr as compared to Rs 81.0 Cr in Q2 last year
- Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Financial Overview (Consolidated) in Rs Cr

Particulars	Q2 FY21	Q2 FY20	Gr %	FH FY21	FH FY20	Gr %
Revenue	431.9	365.6	18.2%	697.9	700.8	-0.4%
Expenditure	304.7	256.7		522.4	496.8	
EBITDA	127.3	108.9	16.9%	175.5	204.0	-14.0%
Adj for Stock Based Compensation & CSR cost	7.4	4.6		13.0	8.5	
Normalised EBITDA	134.7	113.5	18.7%	188.5	212.5	-11.3%
Normalised Margins	31.2%	31.0%		27.0%	30.3%	
Other income	12.9	14.8		24.3	29.2	
PBT	116.6	102.3	14.0%	154.7	191.7	-19.3%
Margins	27.0%	28.0%		22.2%	27.4%	
PAT	87.1	81.0	7.5%	115.5	140.1	-17.6%
Margins	20.2%	22.2%		16.5%	20.0%	
EPS (Basic)	10.34	9.77	5.8%	13.79	16.91	-18.4%
EPS (Diluted)	10.31	9.75	5.7%	13.75	16.86	-18.4%



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Mittali Bharti
Adfactors PR

+91 9871154558
mittali.bharti@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.